It says what too many people need to hear but rarely do: Struggling with your weight is not a personal failure
Disclosures: Annette Bellar: Nothing to Disclose, Nasser Sangwan: Nothing to Disclose, Avinash Kumar: Nothing to Disclose, Muaz Alsabbagh Alchirazi: Nothing to Disclose, Pugazhendhi Kannan: Nothing to Disclose, Amy Attaway: Nothing to Disclose, Saurabh Mishra: Nothing to Disclose, Nicole Welch: Nothing to Disclose, Srinivasan Dasarathy: Nothing to Disclose 702 GLP-1 RECEPTOR AGONISTS HAVE A POTENTIAL TO IMPROVE DISEASE ACTIVITY IN PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE Andrea Tou 1 Jennifer Panganiban 2 , 1 Children's Hospital of Philadelphia, 2 The Children's Hospital of Philadelphia Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common chronic liver disease in children and is characterized by hepatic steatosis with 1 cardiometabolic risk factor

GLP-1 receptors in the brain are heterogeneous and may exert different effects depending on the region and second messenger pathways involved, suggesting the existence of different functional subtypes
109 For example, some mouse models of profound hepatic IR exhibit increased G6pc (glucose-6-phosphatase) expression suggesting increased FOXO1 activity